...
首页> 外文期刊>European review for medical and pharmacological sciences. >MiR-92b inhibits proliferation and invasion of lung cancer by targeting EZH2
【24h】

MiR-92b inhibits proliferation and invasion of lung cancer by targeting EZH2

机译:MiR-92B通过靶向EzH2抑制肺癌的增殖和侵袭

获取原文
           

摘要

OBJECTIVE: To verify that miR-92b inhibits proliferation and invasion of lung cancer by targeting EZH2. MATERIALS AND METHODS: The expression levels of miR-92b and EZH2 in human bronchial epithelial cell line BEAS-2B and human lung cancer cell line (A549, NCI-H23, NCI-H358, NCI-H1975, PC-9) were detected, and miR-92b mimic, sh-EZH2 expression vector, and plasmid blank vector (blank group) were constructed. Blank group, miR-92b mimic, miR-92b mimic+sh-EZH2 group (combined group) were set up, MTT and transwell were used to detect the proliferation and invasion ability of A549 and NCI-H23 cells, and fluorescein report verified the regulatory relationship of miR-92b to EZH2. RESULTS: The expression level of miR-92b in A549, NCI-H23, NCI-H358, NCI-H1975, and PC-9 cells was lower than that in BEAS-2B cells (p0.05). The expression level of EZH2 was higher than that of BEAS-2B cells (p0.05). A549 and NCI-H23 cells were selected for transfection. After that, the expression level of miR-92 in miR-92b mimic, combined group A549 and NCI-H23 cells was higher than that in blank group (p0.05), and miR-92b mimic had no difference with joint group (p0.05). The expression level of EZH2 in cells of miR-92b mimic, blank group A549, and NCI-H23 was lower than that of combined group (p0.05), and miR-92b mimic was lower than that of blank group (p0.05). After the overexpression of miR-92b, pmirGLO-EZH2-3’UT Wt luciferase activity decreased significantly (p0.05) but had no effect on pmirGLO-EZH2-3’UTR Mut Luciferase activity (p0.05). Cell proliferation ability and invasion ability of A549 cells and NCI-H23 cells in miR-92b mimic group were lower than those in blank group (p0.05), while those in combined group were higher than those in miR-92b mimic group (p0.05). CONCLUSIONS: MiR-92b inhibits proliferation and invasion of lung cancer cells through targeted inhibition of EZH2, which is a potential target for future treatment of lung cancer.
机译:目的:验证miR-92b通过靶向EzH2抑制肺癌的增殖和侵袭。检测MIR-92B和EZH2在人支气管上皮细胞系BEAS-2B和人肺癌细胞系(A549,NCI-H23,NCI-H358,NCI-H1975,PC-9)中的表达水平,构建了MiR-92B模拟,SH-EZH2表达载体和质粒斑载体(空白组)。设立空白组miR-92b模拟MiR-92b Mimic + Sh-EzH2组(组合组),MTT和Transwell用于检测A549和NCI-H23细胞的增殖和侵袭能力,荧光素报告验证了miR-92b对EzH2的调节关系。结果:A549,NCI-H23,NCI-H358,NCI-H1975和PC-9细胞中miR-92b的表达水平低于BEA-2b细胞中的miR-92b(P <0.05)。 EZH2的表达水平高于BEA-2B细胞(P <0.05)。选择A549和NCI-H23细胞进行转染。之后,miR-92b模拟中MiR-92的表达水平高于空白组中的miR-92,组合组A549和NCI-H23细胞(P <0.05),miR-92b模仿与关节组没有差异(p > 0.05)。 MIR-92B模拟,坯料组A549和NCI-H23细胞中EZH2的表达水平低于组合基团(P <0.05),MIR-92B模拟物低于空白组(P <0.05) )。在MiR-92b过表达后,PMIRGLO-EZH2-3'UT WT荧光素酶活性显着降低(P <0.05),但对PMIRGLO-EZH2-3'UTR MUTR型Mutr型酶活性(P> 0.05)没有影响。 miR-92b模拟基团A549细胞和NCI-H23细胞的细胞增殖能力和侵袭能力低于空白组(P <0.05),而组合组的细胞增殖能力低于miR-92b模拟组(p <0.05)。结论:MiR-92B通过靶向抑制EZH2抑制肺癌细胞的增殖和侵袭,这是未来治疗肺癌的潜在目标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号